Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,321 to 4,340 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Retrospective vs Prospective: deaths from any cause | 50 of 991 15 of 489 | 2.0 points -0.3 to 3.9 | 1,480 | NCT03426124 An International Pulmonary Embolism Registry Using EKOS |
| Retrospective vs Prospective: serious adverse events | 100 of 991 39 of 489 | 2.1 points -1.1 to 5.0 | 1,480 | NCT03426124 An International Pulmonary Embolism Registry Using EKOS |
| ADG20 IM - Cohort B vs Placebo IM - Cohort B: Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PrEP) | 12 of 752 40 of 728 | -3.9 points -5.9 to -2.0 | 1,480 | NCT04859517 Evaluation of ADG20 for the Prevention of COVID-19 |
| ADG20 IM - Cohort B vs Placebo IM - Cohort B: Percentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by Serology (PrEP) | 10 of 752 18 of 728 | -1.1 points -2.7 to 0.3 | 1,480 | NCT04859517 Evaluation of ADG20 for the Prevention of COVID-19 |
| Restrictive Fluids vs Liberal Fluids: Initiation of Renal Replacement Therapy | 24 of 738 24 of 738 | 0.0 points -1.9 to 1.9 | 1,476 | NCT03434028 Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis |
| IV Abatacept vs SC Abatacept: serious adverse events | 206 of 731 199 of 744 | 1.4 points -3.1 to 6.0 | 1,475 | NCT00559585 Methotrexate-Inadequate Response Study |
| Retrospective vs Prospective: Number of Patients Needing an IVC Filter Placement | 50 of 991 20 of 483 | 0.9 points -1.6 to 3.0 | 1,474 | NCT03426124 An International Pulmonary Embolism Registry Using EKOS |
| Arm I (Chemotherapy) vs Arm II (Chemotherapy, Bevacizumab): serious adverse events | 424 of 738 563 of 735 | -19.1 points -23.8 to -14.4 | 1,473 | NCT00324805 Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery |
| 10% Povidone-iodine (1% Free Iodine) in Purified Water vs 4% Chlorhexidine Gluconate (CHG) in Purified Water: Number of Participants With an Unplanned Fracture-Related Reoperation | 118 of 734 115 of 738 | 0.5 points -3.2 to 4.2 | 1,472 | NCT03385304 Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures |
| Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Composite of the Following Events, Adjudicated Centrally: Stroke, Transient Ischemic Attack, Non-central Nervous System Systemic Embolism, Myocardial Infarction and Cardiovascular Death | 5 of 978 5 of 492 | -0.5 points -1.9 to 0.4 | 1,470 | NCT01674647 Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion |
| Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Composite of Strokes, Transient Ischemic Attacks, Non-central Nervous System Systemic Embolisms, Myocardial Infarctions and All-cause Mortality | 6 of 978 6 of 492 | -0.6 points -2.1 to 0.4 | 1,470 | NCT01674647 Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion |
| Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With All-cause Mortality | 5 of 978 3 of 492 | -0.1 points -1.3 to 0.7 | 1,470 | NCT01674647 Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion |
| Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Composite of Strokes and Non-central Nervous System Systemic Embolisms | 2 of 978 3 of 492 | -0.4 points -1.6 to 0.3 | 1,470 | NCT01674647 Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion |
| Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Non-central Nervous System Systemic Embolisms | 0 of 978 1 of 492 | -0.2 points -1.1 to 0.2 | 1,470 | NCT01674647 Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion |
| Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Strokes | 2 of 978 2 of 492 | -0.2 points -1.3 to 0.4 | 1,470 | NCT01674647 Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion |
| Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Cardiovascular Deaths | 4 of 978 2 of 492 | 0.0 points -1.1 to 0.7 | 1,470 | NCT01674647 Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion |
| Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Myocardial Infarctions | 1 of 978 1 of 492 | -0.1 points -1.0 to 0.4 | 1,470 | NCT01674647 Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion |
| Denosumab 60 mg Q6M vs Placebo: Number of Participants With Any Fracture Through Month 36 | 38 of 734 53 of 734 | -2.0 points -4.6 to 0.4 | 1,468 | NCT00089674 AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer |
| Denosumab 60 mg Q6M vs Placebo: Number of Participants With Any Fracture Through Month 24 | 32 of 734 45 of 734 | -1.8 points -4.1 to 0.5 | 1,468 | NCT00089674 AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer |
| Alteplase Active Control Group vs Tenecteplase Treatment Group: deaths from any cause | 44 of 736 34 of 732 | 1.3 points -1.0 to 3.7 | 1,468 | NCT04915729 A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity |
Code
curl "https://conductscience.org/api/comparisons/v1?page=217"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=217
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03426124-deaths",
"title": "Retrospective vs Prospective: deaths from any cause",
"summary": "50 of 991 against 15 of 489; risk difference 2.0 points, 95% interval -0.3 to 3.9; NCT03426124, An International Pulmonary Embolism Registry Using EKOS",
"record": "/library/comparisons/NCT03426124-deaths",
"nct_id": "NCT03426124",
"kind": "deaths",
"participants": 1480,
"risk_difference": {
"value": 0.019779240155262393,
"lower": -0.002947264243403018,
"upper": 0.03933928676641793
},
"group_1": "50 of 991",
"group_2": "15 of 489",
"difference": "2.0 points",
"interval": "-0.3 to 3.9",
"trial_title": "An International Pulmonary Embolism Registry Using EKOS"
},
{
"id": "NCT03426124-sae",
"title": "Retrospective vs Prospective: serious adverse events",
"summary": "100 of 991 against 39 of 489; risk difference 2.1 points, 95% interval -1.1 to 5.0; NCT03426124, An International Pulmonary Embolism Registry Using EKOS",
"record": "/library/comparisons/NCT03426124-sae",
"nct_id": "NCT03426124",
"kind": "serious-adverse-events",
"participants": 1480,
"risk_difference": {
"value": 0.021153572335064666,
"lower": -0.011232778371752385,
"upper": 0.050279717863004586
},
"group_1": "100 of 991",
"group_2": "39 of 489",
"difference": "2.1 points",
"interval": "-1.1 to 5.0",
"trial_title": "An International Pulmonary Embolism Registry Using EKOS"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=218",
"request_id": "3FTE2yCHwn0HCLd0"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant